DBDaiana D. Becker-Santos

Daiana D. Becker-Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daiana D. Becker-Santos has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nuclear Factor I/B: A Master Regulator of Cell Differentiation with Paradoxical Roles in Cancer

    by Daiana D. Becker-Santos, Kim M. Lonergan, Richard M. Gronostajski, Wan L. Lam


  • Open Access

    Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis

    by Erin A. Marshall, Kevin W. Ng, Sonia H. Y. Kung, Emma M. Conway, Victor D. Martinez, Elizabeth C. Halvorsen, David A. Rowbotham, Emily A. Vucic, Adam W. Plumb, Daiana D. Becker-Santos, et al.

    Lung cancer is a leading cause of cancer-related deaths worldwide. Lung cancer risk factors, including smoking and exposure to environmental carcinogens, have been linked to chronic inflammation. An integral feature of inflammation is the activation, expansion and infiltration of diverse immune cell types, including CD4+ T cells. Within this T cell subset are immunosuppressive regulatory T (Treg) cells and pro-inflammatory T helper 17 (Th17) cells that act in a fine balance to regulate appropriate adaptive immune responses. In the context of lung cancer, evidence suggests that Tregs promote metastasis and metastatic tumor foci development. Additionally, Th17 cells have been shown to be an integral component of the inflammatory milieu in the tumor microenvironment, and potentially involved in promoting distinct lung tumor phenotypes. Studies have shown that the composition of Tregs and Th17 cells are altered in the tumor microenvironment, and that these two CD4+ T cell subsets play active roles in promoting lung cancer progression and metastasis. We review current knowledge on the influence of Treg and Th17 cells on lung cancer tumorigenesis, progression, metastasis and prognosis. Furthermore, we discuss the potential biological and clinical implications of the balance among Treg/Th17 cells in the context of the lung tumor microenvironment and highlight the potential prognostic function and relationship to metastasis in lung cancer.


  • Open Access

    Developmental transcription factor NFIB is a putative target of oncofetal miRNAs and is associated with tumour aggressiveness in lung adenocarcinoma

    by Daiana D Becker-Santos, Kelsie L Thu, John C English, Larissa A Pikor, Victor D Martinez, May Zhang, Emily A Vucic, Margaret Ty Luk, Anita Carraro, Jagoda Korbelik, et al.

    Genes involved in fetal lung development are thought to play crucial roles in the malignant transformation of adult lung cells. Consequently, the study of lung tumour biology in the context of lung development has the potential to reveal key developmentally relevant genes that play critical roles in lung cancer initiation/progression. Here, we describe for the first time a comprehensive characterization of miRNA expression in human fetal lung tissue, with subsequent identification of 37 miRNAs in non-small cell lung cancer (NSCLC) that recapitulate their fetal expression patterns. Nuclear factor I/B (NFIB), a transcription factor essential for lung development, was identified as a potential frequent target for these ‘oncofetal’ miRNAs. Concordantly, analysis of NFIB expression in multiple NSCLC independent cohorts revealed its recurrent underexpression (in ∼40–70% of tumours). Interrogation of NFIB copy number, methylation, and mutation status revealed that DNA level disruption of this gene is rare, and further supports the notion that oncofetal miRNAs are likely the primary mechanism responsible for NFIB underexpression in NSCLC. Reflecting its functional role in regulating lung differentiation, low expression of NFIB was significantly associated with biologically more aggressive subtypes and, ultimately, poorer survival in lung adenocarcinoma patients. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • Open Access

    miRNA expression in human lung cancer and fetal lung: a comparative study

    by Daiana D Becker-Santos, Kelsie L Thu, Patricia P Reis, Wendy P Robinson, Stephen Lam, Wan L Lam

  • Open Access

    Molecular features in arsenic-induced lung tumors

    by Roland Hubaux, Daiana D Becker-Santos, Katey Ss Enfield, David Rowbotham, Stephen Lam, Wan L Lam, Victor D Martinez

    Arsenic is a well-known human carcinogen, which potentially affects ~160 million people worldwide via exposure to unsafe levels in drinking water. Lungs are one of the main target organs for arsenic-related carcinogenesis. These tumors exhibit particular features, such as squamous cell-type specificity and high incidence among never smokers. Arsenic-induced malignant transformation is mainly related to the biotransformation process intended for the metabolic clearing of the carcinogen, which results in specific genetic and epigenetic alterations that ultimately affect key pathways in lung carcinogenesis. Based on this, lung tumors induced by arsenic exposure could be considered an additional subtype of lung cancer, especially in the case of never-smokers, where arsenic is a known etiological agent. In this article, we review the current knowledge on the various mechanisms of arsenic carcinogenicity and the specific roles of this metalloid in signaling pathways leading to lung cancer.


  • Open Access

    Arsenic, asbestos and radon: emerging players in lung tumorigenesis

    by Roland Hubaux, Daiana D Becker-Santos, Katey Ss Enfield, Stephen Lam, Wan L Lam, Victor D Martinez

    The cause of lung cancer is generally attributed to tobacco smoking. However lung cancer in never smokers accounts for 10 to 25% of all lung cancer cases. Arsenic, asbestos and radon are three prominent non-tobacco carcinogens strongly associated with lung cancer. Exposure to these agents can lead to genetic and epigenetic alterations in tumor genomes, impacting genes and pathways involved in lung cancer development. Moreover, these agents not only exhibit unique mechanisms in causing genomic alterations, but also exert deleterious effects through common mechanisms, such as oxidative stress, commonly associated with carcinogenesis. This article provides a comprehensive review of arsenic, asbestos, and radon induced molecular mechanisms responsible for the generation of genetic and epigenetic alterations in lung cancer. A better understanding of the mode of action of these carcinogens will facilitate the prevention and management of lung cancer related to such environmental hazards.


  • Aberrant Expression of Long Noncoding RNAs in Cervical Intraepithelial Neoplasia

    by Ewan A. Gibb, Daiana D. Becker-Santos, Katey S.S. Enfield, Martial Guillaud, Dirk van Niekerk, Jasenka P. Matisic, Calum E. MacAulay, Wan L. Lam


  • Abstract B15: Genomic and epigenomic events in arsenic-related lung squamous cell carcinomas from smokers and never smokers

    by Daiana D. Becker-Santos, Emily A. Vucic, Stephen Lam, Wan L. Lam, Victor D. Martinez

    Background: Arsenic is a well-known human carcinogen. An estimated of 160 million people (∼2% of total human population) are exposed to levels above the recommended threshold (10 μg/L) in Bangladesh, Taiwan, Mongolia, India, China, Argentina, Mexico, Canada, USA, and Chile, among others countries. Skin, bladder, liver, kidney and lungs are the main targets of arsenic carcinogenicity. Lung cancer (LC) is the most deadly form of neoplasia associated to arsenic ingestion. Additionally, lung squamous cell carcinomas (SqCC) occur at higher rates than other LC subtypes following exposure to this metalloid. Both genetic and epigenetic changes (some of them related to arsenic biotransformation) have been proposed to drive carcinogenesis; however, mechanisms are not fully understood. Here, we have compiled a panel of lung tumors from a population with chronic arsenic exposure, including a rare set of lung SqCC from patients who have never smoked. We analyzed to identify whole genome arsenic associated copy-number alterations (CNAs), copy-number variations (CNVs) and global DNA methylation changes. Methods: 52 lung SqCC were analyzed by whole-genome tiling path comparative genomic hybridization for CNA. Twenty-two were from arsenic exposed patients from Chile (10 never smokers and 12 smokers), and 30 additional non-exposed cases were from North America. In addition, 22 blood samples from healthy individuals from Northern Chile were examined to identify naturally occurring germline CNVs. Global DNA methylation analyses for 5 arsenic-exposed cases from never smokers were performed using Illumina's Infinium Human Methylation 450K array. Results: We identified arsenic related CNAs occurring in lung SqCC from patients with chronic exposure to this. The most recurrent events were represented by DNA losses at chromosomes 1q21.1, 7p22.3, 9q12, and 19q13.31. Also, we observed a single arsenic-associated DNA gain at 19q13.33, which contains genes related to single strand DNA breaks repair and neoplastic processes. Interestingly, alterations in this region have been reported to be more frequent among lung adenocarcinomas from never smokers compared with smokers. Additionally, distinctive DNA methylation patterns were associated to arsenic related lung SqCC from never smokers, indicating these changes can have an impact on carcinogenic mechanisms for this subgroup of lung tumors Conclusions: Our study provides insights into the molecular mechanisms of arsenic-induced lung SqCC. Moreover, findings specifically associated to cases among never smokers contribute to understand malignant events occurring in this rare subgroup of lung tumors. The unique and recurrent set of arsenic-associated genetic and epigenetic alterations suggests that this group of tumors may be considered as a distinct disease subclass. Finally, elucidation of the mechanisms underlying the initiation and promotion of carcinogenesis related to arsenic biotransformation processes is of foremost importance to the development of early detection protocols and treatment options for affected individuals.

  • Abstract A4: An expression map of long noncoding RNAs in human lung and non-small cell lung cancer

    by Daiana D. Becker-Santos, Ewan E. Gibb, Emily A. Vucic, Katey S.S. Enfield, Greg L. Stewart, Calum E. MacAulay, Stephen Lam, Wan L. Lam

    Background: Although still largely unexplored, long non-coding RNAs (lncRNAS) are emerging as an integral functional component of the human transcriptome. LncRNAs are mRNA-like transcripts of at least 200 nucleotides (nts) with no protein-coding capacity. Similar to their protein-coding counterparts, lncRNAs are frequently spliced and polyadenylated, but act at the RNA level. The range of functions described for lncRNAs is extensive, and includes key biological roles in chromatin remodeling, alternative splicing and mRNA degradation. Given their biological functions, dysregulation of lncRNAs is rising as an important feature of many disorders, including malignant transformation. However, the extent of the contribution of differential lncRNA expression to normal lung tissue and lung cancer has not been investigated in a comprehensive manner. Hypothesis: We hypothesized that lncRNAs are expressed in a lung tissue-specific manner and that non-small-cell lung cancer (NSCLC) exhibits aberrant lncRNA expression patterns. Methods: Serial Analysis of Gene Expression (SAGE) libraries were used to characterize polyadenylated transcripts in lung tissue compared to a panel of 25 different normal human tissues, and to a cohort of 12 NSCLCs. To generate lncRNA expression profiles, we developed a lncRNA discovery pipeline to map-tag-to-lncRNA matches. To identify differentially expressed lncRNAs we used a permutation test based statistical analysis. Expression pattern in lung tumors were compared to profiles from a variety of cancer types in order to identify lncRNA changes prominent in lung cancer. Results: Here we show that large-scale expression profiling through SAGE, is an effective resource for investigating the expression pattern of polyadenylated lncRNAs. Applying a novel lncRNA discovery pipeline we reveal extensive, tissue-specific lncRNA expression in normal lung compared to a panel of several different normal human tissues. Importantly, our study reveals that NSCLC demonstrate significantly altered lncRNA expression patterns and identify highly dysregulated transcripts associated with this malignancy as oppose to other types of cancer. Conclusion: Collectively, our findings support an important role for tissue-specific lncRNAs in lung cancer. Characterization of the functional role of these transcripts will have a considerable impact on our understanding of lung cancer development and progression, and may reveal clinically important biomarkers.